Birchtech Raises $16.6M, Wins $78M Judgment, Posts 19.8% Q4 Product Revenue Gain
Birchtech raised $16.6 million in a February 2026 NYSE American uplisting and secured a $78 million patent infringement judgment. Fourth-quarter 2025 product revenues grew 19.8% to $3.6 million, net loss narrowed to $0.6 million, and $0.9 million in purchase orders for SEA-IX resin and water filtration media.
1. NYSE American Uplisting and Capital Raise
Birchtech uplisted to the NYSE American in February 2026, raising $16.6 million in gross proceeds through a public offering, including the underwriters' partial over-allotment option. The capital infusion strengthens the Company's balance sheet and expands its investor base ahead of planned growth initiatives.
2. Patent Infringement Judgment and Collection Efforts
The U.S. District Court for the District of Delaware granted Birchtech a final patent infringement judgment of approximately $78 million, up from the original $57 million jury verdict. Birchtech has initiated collection and enforcement actions while defendants pursue an appeal.
3. Fourth Quarter 2025 Financial Performance
In the fourth quarter ended December 31, 2025, Birchtech reported product revenues of $3.6 million, up 19.8% year-over-year, and total revenues of $3.8 million. Net loss improved to $0.6 million and SG&A expenses declined 42%, driven by lower patent litigation costs, while cash stood at $2.2 million with no debt.
4. New Product Launches and Commercial Developments
Birchtech launched SEA-IX™, a nuclear-grade ion exchange resin for potable and industrial wastewater, and secured $0.9 million in purchase orders for filtration media replacements from a mid-Atlantic power utility. The Company also partnered on RSSCT testing with an engineering firm and validated its carbon rejuvenation process with PFAS removal demonstrations.